Inhibition of CCR3 is expected to provide a robust therapeutic approach for the treatment of aging-associated neuroinflammatory diseases, particularly those associated with excessive T-cell infiltration such as multiple sclerosis and Parkinson’s disease. The gene discussed is CCR3; the disease is multiple sclerosis.